Study Stopped
Insufficient recruitment
Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy
1 other identifier
interventional
3
0 countries
N/A
Brief Summary
The purpose of this study is to determine if omega-3 polyunsaturated fatty acids as a monotherapy have antidepressant effects during pregnancy. It will also provide pilot data pertaining to relationships between apparent response to omega-3 monotherapy and both plasma cytokine and erythrocyte essential fatty acid concentrations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for early_phase_1
Started May 2011
Shorter than P25 for early_phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2012
CompletedFirst Submitted
Initial submission to the registry
March 30, 2017
CompletedFirst Posted
Study publicly available on registry
April 5, 2017
CompletedApril 28, 2017
April 1, 2017
9 months
March 30, 2017
April 26, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
The Hamilton Rating Scale for Depression (HAM-D)
The HAM-D is a multiple item semi-structured clinician administered questionnaire used to assess the range, type and severity of depressive symptoms observed in patients with MDD. The HAM-D24 consists of 24 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The HAMD-24 total score is calculated as the sum of the 24 individual symptom scores; the total score can range from 0 to 76. Higher HAMD-24 scores indicate more severe depression.
Subjects were administered the HAM-D at Day 1 and every month thereafter until week 38 of their pregnancies.
Montgomery-Asberg Depression Scale (MADRS)
The MADRS is a clinician administered semi-structured scaled designed to detect changes in depressive symptoms. The scale contains 10 items and ratings are graded from 0 to 6 , with 0 representing an absence of a symptom and 6 corresponding to the most severe degree of MDD symptomology.
Subjects were administered the MADRS on Day 1 and every month thereafter until week 38 of their pregnancies.
Edinburgh Postnatal Depression Scale (EPDS)
The EPDS is a self-administered depression screen for postpartum women. The EPDS consists of 10 questions. Responses are scored 0,, 1, 2, or 3 according to increased severity of the symptom. Items marked with an \* are reversed scored. A total score of 13 or more suggests follow-up intervention is warranted.
Subjects were asked to complete the EPDS on Day 1 and every month thereafter until week 38 of their pregnancies
Beck Depression Scale (BDI)
The BDI is a self-administered questionnaire developed to detect, assess, and monitor changes in depressive symptoms. It is composed of 21 items, each with 4 possible responses scored from 0 to 3 with 3 indicating a higher level of severity. For people who have been clinically diagnosed, scores from 0 to 9 represent minimal depressive symptoms, scores of 10 to 16 indicate mild depression, scores of 17 to 29 indicate moderate depression, and scores of 30 to 63 indicate severe depression.
Subjects were asked to complete the BDI on Day 1 and every month thereafter through week 38 of their pregnancies
Study Arms (1)
Supplementation
EXPERIMENTALSubjects received Omega-3 PUFA supplementation
Interventions
Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
Eligibility Criteria
You may qualify if:
- Women with uncomplicated pregnancy within the 1st or 2nd trimester of pregnancy
- Score of 10 or greater on the nine item Patient Health Questionnaire (PHQ-9) for depression
You may not qualify if:
- antidepressant use in preceding month
- use in previous 4 weeks of psychotropic medications other than hypnotics or benzodiazepines in diazepam dose-equivalents greater than or equal to 2mg/day for insomnia
- Fish allergy
- initiation of regularly scheduled course of psychotherapy within previous 2 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- William Coryelllead
Related Publications (4)
Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Disord. 2002 May;69(1-3):15-29. doi: 10.1016/s0165-0327(01)00374-3.
PMID: 12103448BACKGROUNDDe Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 2003 Nov 7;73(25):3181-7. doi: 10.1016/j.lfs.2003.02.001.
PMID: 14561523BACKGROUNDPeet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998 Mar 1;43(5):315-9. doi: 10.1016/s0006-3223(97)00206-0.
PMID: 9513745BACKGROUNDRees AM, Austin MP, Owen C, Parker G. Omega-3 deficiency associated with perinatal depression: case control study. Psychiatry Res. 2009 Apr 30;166(2-3):254-9. doi: 10.1016/j.psychres.2007.12.011. Epub 2009 Mar 5.
PMID: 19268372BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 30, 2017
First Posted
April 5, 2017
Study Start
May 1, 2011
Primary Completion
February 1, 2012
Study Completion
February 1, 2012
Last Updated
April 28, 2017
Record last verified: 2017-04
Data Sharing
- IPD Sharing
- Will not share
The Investigator does not intend to share IPD